A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

The term "blue chip" originated from poker, where blue chips were the highest denomination of chips used in the game.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk said it had been able to ease some of the restrictions on the supply of starting doses of Wegovy, starting with the US, that were introduced to try to cope with the massive demand for ...

Novo Nordisk said that the launch of Wegovy had “unlocked” the obesity market, despite well-documented supply constraints, but that it is now expanding its focus beyond weight loss to ...

The Kokomo woman was pre-diabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

Veru said Monday that its investigational drug helped preserve lean mass in patients taking the obesity treatment Wegovy, though some experts were skeptical that the topline results were adequate ...

Clothing brands are among the businesses benefiting from the GLP-1 boom as users treat their slimmer selves Tori Allen says she's thrilled to have lost 80 pounds since she went on Wegovy ...

A major analysis of more than 1.2 million medical records has found popular diabetes and weight loss drugs, including Ozempic and Wegovy, may also reduce the risk of other health issues.